Brezden‐Masley C, Fathers KE, Coombes ME, et al. - By analyzing data from a publicly funded health‐care system in Ontario, researchers investigated the occurrence, management, as well as resource utilization according to early vs de novo metastatic disease in Ontario women suffering from triple‐negative breast cancer (TNBC). They found 3,271 cases in total, including 3,081 with stage I‐III and 190 with stage IV TNBC. Cases with stage I‐III disease (n = 2,979, 96.7%) were most often treated with surgery; neoadjuvant therapy was received by 557 (18.7%) and adjuvant therapy by 1,974 (66.3%), the latter at a median of 44 days after surgery, and among patients with stage I‐III disease, radiation was received by 2,446 (79.4%). Anthracyclines/taxanes were top drug regimens used. Four times higher annual per‐patient health care costs were reported for stage IV vs stage I‐III TNBC. Overall, findings revealed that use of all treatment modalities was less frequent in metastatic TNBC vs early TNBC but still the former was associated with higher per‐patient costs. Treatment patterns were aligned with the choices available at the time; however, low rates of neoadjuvant treatment were documented.